English
Regional settings| Spread | 0.30 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 4.89 |
| Open | 4.98 |
| 1-Year Change | 601.41% |
| Day's Range | 4.84 - 5.07 |
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of resistant cancers and viruses through the development of its drug candidates. The Company has three product pipelines: Annamycin, WP1066 and WP1122. Annamycin is developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). WP1066 is a immune or transcription modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α. WP1122 is a prodrug of 2-deoxy-D-glucose (2-DG), which provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells.
BRIEF: For the nine months ended 30 September 2021, Moleculin Biotech Inc revenues was not reported. Net loss decreased 11% to $13.1M. Lower net loss reflects Gain from change in fair value of warran increase from $1.5M to $4.4M (income), Research and development balancing value decrease of 2% to $10.5M (expense), Interest Income, Net increase from $10K to $236K (income).
